Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

W H Harvey

Showing results (11-20 of 17) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 17 results.
Leukemia Research|August 1, 1994
Interferon-alpha-2b downregulation of oncogenes H-ras, c-raf-2, c-kit, c-myc, c-myb and c-fos in ESKOL, a hairy cell leukemic line, results in temporal perturbation of signal transduction cascadeW H Harvey, O S Harb, S T Kosak, et al.
Investigational New Drugs|February 1, 1993
Phase II study of trimetrexate in previously untreated patients with hepatocellular carcinoma. Southwest Oncology Group study 8712W H Harvey, T R Fleming, P J Goodman, et al.
Cancer Investigation|January 1, 1997
Oral ondansetron 8 mg twice daily is as effective as 8 mg three times daily in the prevention of nausea and vomiting associated with moderately emetogenic cancer chemotherapy. S3A-376 Study GroupT M Beck, M York, A Chang, et al.
Anti-Cancer Drugs|April 1, 1994
Didemnin B in metastatic malignant melanoma: a phase II trial of the Southwest Oncology GroupV K Sondak, K J Kopecky, P Y Liu, et al.
Annals of Internal Medicine|March 15, 1993
Efficacy of oral ondansetron in the prevention of emesis in outpatients receiving cyclophosphamide-based chemotherapy. The Ondansetron Study GroupT M Beck, A A Ciociola, S E Jones, et al.
Seminars in Oncology|August 1, 1992
The delayed-emesis syndrome from cisplatin: phase III evaluation of ondansetron versus placeboD R Gandara, W H Harvey, G G Monaghan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 1, 1994
A randomized, double-blind comparison of intravenous ondansetron alone and in combination with intravenous dexamethasone in the prevention of high-dose cisplatin-induced emesisP J Hesketh, W H Harvey, W G Harker, et al.
Pageof 2

Showing results (11-20 of 17) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 17 results.
Leukemia Research|August 1, 1994
Interferon-alpha-2b downregulation of oncogenes H-ras, c-raf-2, c-kit, c-myc, c-myb and c-fos in ESKOL, a hairy cell leukemic line, results in temporal perturbation of signal transduction cascadeW H Harvey, O S Harb, S T Kosak, et al.
Investigational New Drugs|February 1, 1993
Phase II study of trimetrexate in previously untreated patients with hepatocellular carcinoma. Southwest Oncology Group study 8712W H Harvey, T R Fleming, P J Goodman, et al.
Cancer Investigation|January 1, 1997
Oral ondansetron 8 mg twice daily is as effective as 8 mg three times daily in the prevention of nausea and vomiting associated with moderately emetogenic cancer chemotherapy. S3A-376 Study GroupT M Beck, M York, A Chang, et al.
Anti-Cancer Drugs|April 1, 1994
Didemnin B in metastatic malignant melanoma: a phase II trial of the Southwest Oncology GroupV K Sondak, K J Kopecky, P Y Liu, et al.
Annals of Internal Medicine|March 15, 1993
Efficacy of oral ondansetron in the prevention of emesis in outpatients receiving cyclophosphamide-based chemotherapy. The Ondansetron Study GroupT M Beck, A A Ciociola, S E Jones, et al.
Seminars in Oncology|August 1, 1992
The delayed-emesis syndrome from cisplatin: phase III evaluation of ondansetron versus placeboD R Gandara, W H Harvey, G G Monaghan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 1, 1994
A randomized, double-blind comparison of intravenous ondansetron alone and in combination with intravenous dexamethasone in the prevention of high-dose cisplatin-induced emesisP J Hesketh, W H Harvey, W G Harker, et al.
Pageof 2